[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hdl\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hdl":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100657851","investigation-of-egg-intake-and-the-relationship-between-gut-microbiome-metabolic-and-immune-profiles-100657851",false,"NCT07844616","Investigation of Egg Intake and the Relationship Between Gut Microbiome, Metabolic, and Immune Profiles","Inclusion Criteria:\n\n* 18-50 years old (at time of screening)\n* Premenopausal status for women\n* Body mass index (BMI) 18.5 to \\\u003C 25 kg\u002Fm2; or ³ 30 kg\u002Fm2 and \\>30% and \\>40% body fat for men and women, respectively\n* Willing to consume whole eggs and egg whites provided during the study on a daily basis, and refrain from other eggs or egg-based foods and beverages during the study\n* Do not fit any exclusion criteria\n\nExclusion Criteria:\n\n* \\\u003C18 years old and ≥ 51 years old\n* BMI \\\u003C18.5, 25-29.9, or body weight \\\u003C 110 pounds\n* Experienced \\>10% weight change in the past 4 weeks\n* Elevated fasting glucose levels (fasting glucose higher than 126 mg\u002FdL) and triglycerides greater than 500 mg\u002FdL, or total cholesterol \\\u003C 120 mg\u002FdL and HDL- cholesterol \\\u003C 15 mg\u002FdL\n* Self-reported and\u002For physician-diagnosed history of severe constipation, diabetes mellitus, coronary heart disease, stroke, renal or liver disease, cancer, eating disorders, certain severe and\u002For relapsing\u002Fremitting autoimmune, inflammatory, intestinal or metabolic diseases, chronic infections, scleroderma, blood clotting disorders, intravenous drug use, or current pregnancy or lactation, postmenopausal\n* Allergy to eggs\n* Implanted medical device (e.g., pacemaker) or other health condition that would prevent measurement of body composition by bioelectrical impedence\n* Currently taking lipid-lowering medications (e.g., statins, fibrates), glucose-regulating medications, anti-inflammatory medications (e.g., NSAIDs, corticosteroids), or medications that primarily affect blood clotting (e.g., warfarin), long-term antibiotics or probiotics in the last 3 months or during the intervention\n* Active smoker",true,"ALL","18 Years","50 Years",{"count":20,"type":21},78,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this intervention study is to investigate the effects of daily egg intake on markers of gut health, high-density lipoprotein (HDL), metabolic, and immune cell profiles in adults with body mass indexes (BMI) in normal and obesity ranges. This study further aims to determine whether egg effects are associated with baseline gut microbiome profiles, and whether egg effects are different between males and females and by BMI status. The study will address the following objectives:\n\nObjective 1: Evaluate the effects of daily egg white vs. whole egg intake on gut health, microbiome, and metabolome profiles.\n\nObjective 2: Evaluate the effects of daily egg white vs. whole egg intake on HDL composition and function.\n\nObjective 3: Evaluate the effects of daily egg white vs. whole egg intake on immune profiles and function in culture (ex vivo).\n\nParticipants will be asked to consume egg whites and whole eggs on a daily basis for 4-weeks each, and avoid eating eggs for a total of 8 weeks at different points in the study. Participants will be asked to complete surveys about dietary intake and physical activity, as well as provide blood and stool samples throughout the course of the study.",[27,28,29,30,31],"Obesity (BMI Equal to or >30)","Immune Function","HDL","Gut Microbiome","Healthy Adult Participants",[33,29,34,35,36,37,38],"Eggs","Obesity","Diet intervention","Nutrition","Gut microbioome","Immune function","RECRUITING","2026-09-22",{"date":42,"type":43},"2026-09-28","ACTUAL",{"date":45,"type":21},"2026-09",{"date":47,"type":21},"2027-12-31",{"name":49,"class":50},"University of Connecticut","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":51},"100530749","relationship-between-high-density-lipoprotein-subtypes-and-coronary-heart-disease-prognosis-100530749","NCT06190834","Relationship Between High-Density Lipoprotein Subtypes and Coronary Heart Disease Prognosis.","Relationship Between High Density Lipoprotein Subtypes and Prognosis in Coronary Heart Disease Patients.","RHDLS-CHD","Inclusion Criteria:\n\n1. The age of the patients is over 18 years old;\n2. Coronary artery disease was confirmed by coronary angiography.\n\nExclusion Criteria:\n\n1. Severe valvular disease, severe myocarditis, severe hepatic and renal insufficiency, thyroid insufficiency, severe infectious or systemic inflammatory diseases, severe blood diseases, malignant tumors.\n2. Lack of data on HDL subtypes.",{"count":61,"type":21},5000,"OBSERVATIONAL","Cardiovascular disease (CVD) is the leading cause of human mortality worldwide, imposing substantial societal and economic burdens. Traditionally, high-density lipoprotein (HDL) has been branded as the \"beneficial\" lipoprotein. The Framingham study found that for every 1mg\u002Fdl increase in HDL, the risk of coronary heart disease (CHD) was reduced by 2% in men and 3% in women. Subsequent studies further affirmed the inverse correlation between HDL and the risk of CHD. However, these findings were first challenged by Mendelian randomization studies which failed to identify a causal relationship between HDL and CHD. Moreover, randomized controlled trials demonstrated that therapeutically increasing plasma HDL concentrations did not reduce the risk of CHD events, prompting doubts about HDL's status as \"good cholesterol.\" The relationship between HDL and CHD might be more intricate than previously believed, possibly not just mediated by the quantity of HDL but also intimately linked with its function.\n\nSeveral cross-sectional studies have confirmed the relationship between HDL subtypes and the severity of disease in CHD patients, yet findings are inconsistent. Conventional testing methods lack a universally accepted standard for defining or describing HDL subfractions, with issues like expensive equipment, poor repeatability, cumbersome operation, slow analysis, and low throughput. Microfluidic electrophoresis technology combines the merits of electrophoresis with microfluidic chip technology. This method facilitates efficient separation of substances in microchannels on a substrate, providing rapid and consistent results. Utilizing the latest microfluidic chip technology for HDL subfraction detection offers quick, accurate, and straightforward analysis with minimal sample volume and automation. It precisely reflects the serum concentrations of HDL subfractions HDL2b and HDL3, addressing the current pitfalls of clinical HDL subfraction analysis methods. This approach is poised to become the standard method for HDL subfraction testing.\n\nIn conclusion, existing studies on the association between HDL subtypes and CHD remain inconsistent, with most having a small sample size. Our study, leveraging microfluidic chip technology for HDL subfraction detection, aims to further investigate: the prognostic value of HDL subtypes for the long-term outcomes of CHD patients, building a risk prediction model for adverse cardiovascular events that includes HDL subtypes.",[29,65],"Coronary Heart Disease",[67,68,65],"High-Density Lipoprotein","Subtypes","2023-12-19",{"date":71,"type":43},"2024-01-05",{"date":73,"type":43},"2023-12-01",{"date":75,"type":21},"2026-08-31",{"name":77,"class":50},"Beijing Tsinghua Chang Gung Hospital"]